乙型肝炎病毒相关肝癌的规范化抗病毒治疗及监管  

The standardized antiviral therapy and supervision of hepatitis B virus-associated hepatocellular carcinoma

作　　者：杨雪梅[1] 陈洁[1] 杨军[1] 袁媛[1] 胡章勇[1] YANG Xuemei, CHEN Jie, YANG Jun, YUAN Yuan, HU Zhangyong(Department of Infectious Disease, the First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, Chin)

机构地区：[1]成都医学院第一附属医院感染科,成都610500

出　　处：《生命的化学》2018年第1期20-24,共5页Chemistry of Life

基　　金：四川省卫生厅项目(130384)

摘　　要：全球癌症报告指出,我国每年新发的肝癌病例和死亡病例约占全球的50%,其中乙型肝炎病毒(hepatitis B virus,HBV)相关肝癌比例约80%。慢性乙型肝炎治疗的重要目标之一是降低肝癌的发生风险。目前,核苷(酸)类似物(nucleoside analogues,NAs)抗病毒治疗被认为是慢性乙型肝炎的核心治疗措施,其与肝细胞癌(hepatocellular carcinoma,HCC)的发生、进展、预后密切相关。文章就HBV相关HCC的抗病毒治疗的研究进展作一综述。The global cancer report pointed out that China＇s annual new cases of liver cancer and deaths account for about 50% of the world, among which the hepatitis B virus（HBV） related hepatocellular carcinoma（HCC） ratio is around 80%. One of the most important goals in the treatment of chronic hepatitis B is to reduce the risk of liver cancer. At present, nucleoside analogues（NAs） antiviral therapy is considered as the core treatment of chronic hepatitis B, which is closely related to the occurrence, progression and prognosis of HCC. This article reviewed the progress of HBV-related HCC antiviral therapy.

关 键 词：乙型肝炎病毒 肝癌 抗病毒治疗 

分 类 号：R512.62[医药卫生—内科学] R735.7[医药卫生—临床医学]